Anti-Yo Positive Paraneoplastic Cerebellar Syndrome in Recurrent Ovarian Carcinoma: A Unique Case to a Rare Phenomenon. by Canakis, Andrew et al.
Lehigh Valley Health Network
LVHN Scholarly Works
Department of Medicine
Anti-Yo Positive Paraneoplastic Cerebellar
Syndrome in Recurrent Ovarian Carcinoma: A
Unique Case to a Rare Phenomenon.
Andrew Canakis
Thomas Quinn DO
Lehigh Valley Health Network, Thomas.Quinn@lvhn.org
Ryan Mayo MD
Lehigh Valley Health Network, ryan.mayo@lvhn.org
Follow this and additional works at: https://scholarlyworks.lvhn.org/medicine
Part of the Medical Sciences Commons
This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Published In/Presented At
Canakis, A. Quinn, T. Mayo, R. (2017, October 28). Anti-Yo Positive Paraneoplastic Cerebellar Syndrome in Recurrent Ovarian
Carcinoma: A Unique Case to a Rare Phenomenon. Poster Presented at: The PA-ACP Eastern Region Abstract and Doctors Dilemma
Competition. Harrisburg, PA.
Andrew Canakis1, Thomas A. Quinn2, Ryan Mayo2
Anti-Yo Positive Paraneoplastic Cerebellar Syndrome in Recurrent Ovarian Carcinoma: 
A Unique Case to a Rare Phenomenon
© 2017 Lehigh Valley Health Network
INTRODUCTION
1Philadelphia College of Osteopathic Medicine, Philadelphia, PA, 2Department of Internal Medicine, Lehigh Valley Health Network, Allentown, PA
•  Paraneoplastic neurological syndromes are an assorted group of symptoms that occur in 1% 
of all malignancies through peripherally stimulated immunological reactions stemming from 
neoplastic-associated metabolic and hormonal aberrancies.1 
•  A rare but fatal subset of this tumor-induced phenomenon is paraneoplastic cerebellar 
degeneration (PCD). With nearly 30 different antibodies associated with PCD, the most common 
subtype is the anti-Yo antibody (anti-Purkinje cell cytoplasmic antibody) which is related to 
nearly 50% of cases.2 
•  Anti-Yo PCD is exceptionally rare, with literature demonstrating anti-Yo positivity in 2.3% of 
ovarian cancer patients, with only 12% of these subjects demonstrating PCD.2,3 
•  PCD is characterized by the progressive development of severely disabling symptoms over a few 
weeks.3 The neurological symptoms of PCD typically precede the clinical diagnosis of cancer.4 
•  We present an extraordinarily unique case of PCD developing 12 years after the initial diagnosis 
of ovarian cancer.
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CASE PRESENTATION
•  An 81-year-old female with recurrent stage IIIC Ovarian cancer s/p chemotherapy with docetaxel 
and carboplatin presented with intractable nausea and vomiting. 
•  She developed these symptoms shortly after her first dose of niraparib, which was initiated as 
salvage therapy. Multiple antiemetics were unsuccessful. She subsequently developed right hand 
tremor, dysarthria, ataxia and diplopia. Levetiracteam, valproic acid, risperidone and clonazepam 
showed limited to no benefit for these involuntary movements.
•  It was initially suspected her symptoms were an acute dystonic reaction related to multiple 
antiepileptic medications.
•  MRI brain revealed multiple nonspecific hyperintense lesions in the white matter along 
periventricular and subcortical distribution. 
•  Diagnostic testing including an EEG and lumbar puncture were negative for causal agents. 
•  A panel of tumor markers revealed positive anti-Yo antibody, confirming paraneoplastic etiology. 
•  Given her intractable symptoms and poor prognosis, she transitioned to comfort measures and 
expired shortly after discharge to hospice.
DISCUSSION
•  The majority of PCD cases in literature demonstrate onset prior to cancer 
diagnosis. To our knowledge, only three other cases have encountered late-
onset PCD in ovarian cancer, with those reports describing onset one year, 
two years, and six years after documented history of ovarian carcinoma.5,6,7,8 
•  We demonstrate a unique case of PCD precipitating twelve years after an 
initial diagnosis of ovarian cancer.
